Literature DB >> 12270865

Normal coronary flow reserve after arterial switch operation for transposition of the great arteries: an intracoronary Doppler guidewire study.

Gylfi Oskarsson1, Erkki Pesonen, Peter Munkhammar, Staffan Sandström, Peeter Jögi.   

Abstract

BACKGROUND: Recent studies performed with positron emission tomography have suggested that coronary flow reserve (CFR) is moderately to severely reduced after the arterial switch operation (ASO). These findings are of great concern but have not been confirmed by other methods. METHODS AND
RESULTS: Eleven symptom-free children were studied between 4 and 11 (median 6.0) years after the ASO. Flow velocity in the left anterior descending (LAD) and right coronary arteries (RCA) was measured with a 0.014-inch Doppler FloWire (Cardiometrics) before and after intracoronary injection of adenosine (0.5 microg/kg) and nitroglycerin (5 microg/kg). CFR was defined as the ratio of hyperemic to basal average peak velocity (APV). The median (range) CFR in the LAD was 3.7 (3.0 to 4.8) and 3.4 (2.9 to 4.8) in the RCA. The increase in APV after intracoronary injection of nitroglycerin was 300% (240% to 420%) in the LAD and 260% (190% to 460%) in the RCA. APV at rest was 15.0 (14.0 to 21.0) cm/s in the LAD and 16.0 (9.6 to 30.0) cm/s in the RCA. A linear relation was found between right ventricular systolic pressure and resting APV in the RCA (r=0.77, P=0.0056), and between resting APV and CFR (r=-0.61, P<0.05) in the RCA.
CONCLUSIONS: The CFR and coronary vasoreactivity to nitroglycerin in children treated for transposition of the great arteries with the ASO was within normal limits. Increased right ventricular pressure and myocardial hypertrophy can cause increased resting coronary flow velocity in the RCA and affect CFR negatively.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12270865     DOI: 10.1161/01.cir.0000030937.27602.bd

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  7 in total

1.  Site of coronary sinus drainage does not significantly affect coronary flow reserve in patients long term after Fontan operation.

Authors:  A Eicken; W Sebening; T Genz; H Kaemmerer; R Lange; R Busch; J Hess
Journal:  Pediatr Cardiol       Date:  2006 Jan-Feb       Impact factor: 1.655

2.  Peripheral Endothelial Function After Arterial Switch Operation for D-looped Transposition of the Great Arteries.

Authors:  Heather Y Sun; Katie Jo Stauffer; Susan E Nourse; Chau Vu; Elif Seda Selamet Tierney
Journal:  Pediatr Cardiol       Date:  2017-03-27       Impact factor: 1.655

3.  Posterior descending coronary artery flow reserve assessment by Doppler echocardiography in children with and without congenital heart defect: comparison with invasive technique.

Authors:  M Aoki; K Harada; M Tamura; M Toyono; G Takada
Journal:  Pediatr Cardiol       Date:  2004 Nov-Dec       Impact factor: 1.655

4.  Use of cardiac magnetic resonance imaging to determine myocardial viability in an infant with in utero septal myocardial infarction and ventricular noncompaction.

Authors:  Jennifer K E Whitham; Babar S Hasan; Marcus S Schamberger; Tiffanie R Johnson
Journal:  Pediatr Cardiol       Date:  2008-01-01       Impact factor: 1.655

5.  Impaired left ventricular function after arterial switch operation: exclusion of significant coronary artery stenosis with an intravascular Doppler guidewire.

Authors:  A Eicken; T Genz; A Kühn; M Hauser; J Hess
Journal:  Pediatr Cardiol       Date:  2003-11-03       Impact factor: 1.655

6.  Late coronary complications after arterial switch operation for transposition of great arteries. Clinical and therapeutic implications.

Authors:  G Agnoletti; F Bajolle; D Bonnet; D Sidi; P Vouhé
Journal:  Images Paediatr Cardiol       Date:  2005-07

7.  Adenosine stress myocardial perfusion scintigraphy in pediatric patients after arterial switch operation.

Authors:  Arun Reddy; Akshay K Bisoi; Suhas Singla; Chetan D Patel; Sambhunath Das
Journal:  Indian J Nucl Med       Date:  2013-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.